2025 Q4 -tulosraportti
69 päivää sitten
‧56 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | - | - | ||
| 100 | - | - | ||
| 15 | - | - | ||
| 148 | - | - | ||
| 332 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 377 422 | 377 422 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 377 422 | 377 422 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 6.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenLarge French study Sponsor - University Hospital, Bordeaux 450 patients and 20 hospitals The ISKIA study is an observational/registry study, which means:* it evaluates patients who already receive imlifidase in clinical routine according to French guidelines* thus not a classic "industry-funded drug trial" https://clinicaltrials.gov/study/NCT07379957?term=Imlifidase&viewType=Card&page=2&rank=14- ·1 päivä sittenCompared to XBI XBI has performed well for a long time. In 2026, there are reasons for American investors to start buying Hansa. Keep an eye on the volume during spring. When Bollinger Bands narrow (”squeeze”), it means that volatility is low and that the price has moved in a tight range. It is often interpreted as the market ”gathering energy” before a larger move. But important nuances: * Narrower bands = low volatility, not direction. * A reaction or breakout often comes after a squeeze, but it can take time. * The move can go up or down – the band says nothing about the direction. * False breakouts are common, especially in sideways markets. Common interpretation in trading: * Squeeze → “preparation phase” * Expansion → “reaction / breakout” Many therefore combine Bollinger Bands with e.g.: * volume (to confirm breakout) * RSI (for overbought/oversold) * support/resistance levels In short: Yes, a reaction becomes more likely when the bands narrow.
- ·1 päivä sittenShort Sellers Two data points: 🇸🇪 Stockholm: approx 4.79% short interest 🇺🇸 OTC (HNSBF): very low shorting (~0.0x % in practice) 📉 Short interest shows a sharp de-escalation of bearish positioning internationally (OTC), but in Stockholm there is still a meaningful but not extreme short exposure (~4.8%). This may indicate that the negative case is no longer expanding, rather than a broad “exit from shorts” already being underway. The negative narrative is already “played out”. https://www.marketbeat.com/stocks/OTCMKTS/HNSBF/short-interest/#google_vignette
- ·1 päivä sittenInvestment Analysis: GBS Exposure in Hansa Biopharma vs Annexon (2026) Summary The current market valuation shows a clear asymmetry between Annexon and Hansa Biopharma despite both companies having exposure to Guillain-Barré syndrome. * Annexon: ~1.15 billion USD * Hansa: ~2.9 billion SEK (~0.27–0.30 billion USD) Annexon is thus valued approximately 4x higher, despite Hansa having a commercial product and a broader pipeline. ⸻ 1. Annexon – close to GBS monetization Annexon represents a classic late-stage biotech case where GBS is the dominant value driver. Clinical and regulatory position * Late clinical phase in GBS * Direct evidence of clinical effect * Close to regulatory decisions Value structure * GBS constitutes ~50–80% of the company value * Other pipeline is secondary Market pricing The market is already discounting a scenario where: GBS is likely to become a commercial product within the foreseeable future 👉 Annexon is thus an event-driven case with a short value realization horizon and high binarity. ⸻ 2. Hansa Biopharma – GBS as an emerging option Hansa has a more complex value profile where GBS is not yet fully priced as a core asset. Evidence base 1. Indirect Phase 2 data (imlifidase in GBS): * Clinical signal in Guillain-Barré syndrome * Validates mechanism in patient population 2. Phase 1 data (HNSA-5487, NICE-01): * Rapid and robust IgG reduction * Confirms biological activity in humans 3. Development strategy: * Planned interactions with FDA * Intention to move towards late clinical phase after 2026 👉 Hansa thus has: * mechanism validation * clinical signal (indirect Phase 2) * next-generation drug candidate But still lacks: * direct late-phase data for HNSA-5487 in GBS 👉 GBS is therefore still an early but growing value driver, rather than a centrally priced asset. ⸻ 📈 Catalysts (Hansa) * FDA interactions (1H 2026) * start of late clinical phase for HNSA-5487 * first patient data in GBS 👉 These constitute the three most important trigger points for potential re-rating: * FDA meetings reduce regulatory uncertainty * Phase 3 initiation moves the program towards value realization * clinical data will be the first real test of the next-generation molecule ⸻ 3. Valuation Implication Annexon * GBS: ~50–80% of EV * The market prices a high probability of commercialization Hansa * GBS: ~10–25% of EV (risk-adjusted theoretical) * The market discounts a significantly lower probability for HNSA-5487 in GBS ⸻ 4. Relative Market Position See image ⸻ 5. Investment Logic Annexon * Priced for GBS to likely be realized * Limited further upside without strong outperformance in data * High binary risk in case of negative outcome Hansa * Priced with low implicit probability for GBS success * Already has a commercial base (imlifidase) * Pipeline provides additional optionality ⸻ 6. Conclusion The market treats: * Annexon as a near-monetizable GBS case * Hansa Biopharma as an early platform case where GBS is not yet priced in 👉 The upside in Hansa is structurally larger because re-rating can occur from a very low base, while Annexon is already trading near a scenario where GBS success is largely discounted.
·1 päivä sittenWhat are people's expectations for Q1?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
69 päivää sitten
‧56 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenLarge French study Sponsor - University Hospital, Bordeaux 450 patients and 20 hospitals The ISKIA study is an observational/registry study, which means:* it evaluates patients who already receive imlifidase in clinical routine according to French guidelines* thus not a classic "industry-funded drug trial" https://clinicaltrials.gov/study/NCT07379957?term=Imlifidase&viewType=Card&page=2&rank=14
- ·1 päivä sittenCompared to XBI XBI has performed well for a long time. In 2026, there are reasons for American investors to start buying Hansa. Keep an eye on the volume during spring. When Bollinger Bands narrow (”squeeze”), it means that volatility is low and that the price has moved in a tight range. It is often interpreted as the market ”gathering energy” before a larger move. But important nuances: * Narrower bands = low volatility, not direction. * A reaction or breakout often comes after a squeeze, but it can take time. * The move can go up or down – the band says nothing about the direction. * False breakouts are common, especially in sideways markets. Common interpretation in trading: * Squeeze → “preparation phase” * Expansion → “reaction / breakout” Many therefore combine Bollinger Bands with e.g.: * volume (to confirm breakout) * RSI (for overbought/oversold) * support/resistance levels In short: Yes, a reaction becomes more likely when the bands narrow.
- ·1 päivä sittenShort Sellers Two data points: 🇸🇪 Stockholm: approx 4.79% short interest 🇺🇸 OTC (HNSBF): very low shorting (~0.0x % in practice) 📉 Short interest shows a sharp de-escalation of bearish positioning internationally (OTC), but in Stockholm there is still a meaningful but not extreme short exposure (~4.8%). This may indicate that the negative case is no longer expanding, rather than a broad “exit from shorts” already being underway. The negative narrative is already “played out”. https://www.marketbeat.com/stocks/OTCMKTS/HNSBF/short-interest/#google_vignette
- ·1 päivä sittenInvestment Analysis: GBS Exposure in Hansa Biopharma vs Annexon (2026) Summary The current market valuation shows a clear asymmetry between Annexon and Hansa Biopharma despite both companies having exposure to Guillain-Barré syndrome. * Annexon: ~1.15 billion USD * Hansa: ~2.9 billion SEK (~0.27–0.30 billion USD) Annexon is thus valued approximately 4x higher, despite Hansa having a commercial product and a broader pipeline. ⸻ 1. Annexon – close to GBS monetization Annexon represents a classic late-stage biotech case where GBS is the dominant value driver. Clinical and regulatory position * Late clinical phase in GBS * Direct evidence of clinical effect * Close to regulatory decisions Value structure * GBS constitutes ~50–80% of the company value * Other pipeline is secondary Market pricing The market is already discounting a scenario where: GBS is likely to become a commercial product within the foreseeable future 👉 Annexon is thus an event-driven case with a short value realization horizon and high binarity. ⸻ 2. Hansa Biopharma – GBS as an emerging option Hansa has a more complex value profile where GBS is not yet fully priced as a core asset. Evidence base 1. Indirect Phase 2 data (imlifidase in GBS): * Clinical signal in Guillain-Barré syndrome * Validates mechanism in patient population 2. Phase 1 data (HNSA-5487, NICE-01): * Rapid and robust IgG reduction * Confirms biological activity in humans 3. Development strategy: * Planned interactions with FDA * Intention to move towards late clinical phase after 2026 👉 Hansa thus has: * mechanism validation * clinical signal (indirect Phase 2) * next-generation drug candidate But still lacks: * direct late-phase data for HNSA-5487 in GBS 👉 GBS is therefore still an early but growing value driver, rather than a centrally priced asset. ⸻ 📈 Catalysts (Hansa) * FDA interactions (1H 2026) * start of late clinical phase for HNSA-5487 * first patient data in GBS 👉 These constitute the three most important trigger points for potential re-rating: * FDA meetings reduce regulatory uncertainty * Phase 3 initiation moves the program towards value realization * clinical data will be the first real test of the next-generation molecule ⸻ 3. Valuation Implication Annexon * GBS: ~50–80% of EV * The market prices a high probability of commercialization Hansa * GBS: ~10–25% of EV (risk-adjusted theoretical) * The market discounts a significantly lower probability for HNSA-5487 in GBS ⸻ 4. Relative Market Position See image ⸻ 5. Investment Logic Annexon * Priced for GBS to likely be realized * Limited further upside without strong outperformance in data * High binary risk in case of negative outcome Hansa * Priced with low implicit probability for GBS success * Already has a commercial base (imlifidase) * Pipeline provides additional optionality ⸻ 6. Conclusion The market treats: * Annexon as a near-monetizable GBS case * Hansa Biopharma as an early platform case where GBS is not yet priced in 👉 The upside in Hansa is structurally larger because re-rating can occur from a very low base, while Annexon is already trading near a scenario where GBS success is largely discounted.
- ·1 päivä sittenWhat are people's expectations for Q1?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | - | - | ||
| 100 | - | - | ||
| 15 | - | - | ||
| 148 | - | - | ||
| 332 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 377 422 | 377 422 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 377 422 | 377 422 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 6.2.2025 |
2025 Q4 -tulosraportti
69 päivää sitten
‧56 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 6.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenLarge French study Sponsor - University Hospital, Bordeaux 450 patients and 20 hospitals The ISKIA study is an observational/registry study, which means:* it evaluates patients who already receive imlifidase in clinical routine according to French guidelines* thus not a classic "industry-funded drug trial" https://clinicaltrials.gov/study/NCT07379957?term=Imlifidase&viewType=Card&page=2&rank=14
- ·1 päivä sittenCompared to XBI XBI has performed well for a long time. In 2026, there are reasons for American investors to start buying Hansa. Keep an eye on the volume during spring. When Bollinger Bands narrow (”squeeze”), it means that volatility is low and that the price has moved in a tight range. It is often interpreted as the market ”gathering energy” before a larger move. But important nuances: * Narrower bands = low volatility, not direction. * A reaction or breakout often comes after a squeeze, but it can take time. * The move can go up or down – the band says nothing about the direction. * False breakouts are common, especially in sideways markets. Common interpretation in trading: * Squeeze → “preparation phase” * Expansion → “reaction / breakout” Many therefore combine Bollinger Bands with e.g.: * volume (to confirm breakout) * RSI (for overbought/oversold) * support/resistance levels In short: Yes, a reaction becomes more likely when the bands narrow.
- ·1 päivä sittenShort Sellers Two data points: 🇸🇪 Stockholm: approx 4.79% short interest 🇺🇸 OTC (HNSBF): very low shorting (~0.0x % in practice) 📉 Short interest shows a sharp de-escalation of bearish positioning internationally (OTC), but in Stockholm there is still a meaningful but not extreme short exposure (~4.8%). This may indicate that the negative case is no longer expanding, rather than a broad “exit from shorts” already being underway. The negative narrative is already “played out”. https://www.marketbeat.com/stocks/OTCMKTS/HNSBF/short-interest/#google_vignette
- ·1 päivä sittenInvestment Analysis: GBS Exposure in Hansa Biopharma vs Annexon (2026) Summary The current market valuation shows a clear asymmetry between Annexon and Hansa Biopharma despite both companies having exposure to Guillain-Barré syndrome. * Annexon: ~1.15 billion USD * Hansa: ~2.9 billion SEK (~0.27–0.30 billion USD) Annexon is thus valued approximately 4x higher, despite Hansa having a commercial product and a broader pipeline. ⸻ 1. Annexon – close to GBS monetization Annexon represents a classic late-stage biotech case where GBS is the dominant value driver. Clinical and regulatory position * Late clinical phase in GBS * Direct evidence of clinical effect * Close to regulatory decisions Value structure * GBS constitutes ~50–80% of the company value * Other pipeline is secondary Market pricing The market is already discounting a scenario where: GBS is likely to become a commercial product within the foreseeable future 👉 Annexon is thus an event-driven case with a short value realization horizon and high binarity. ⸻ 2. Hansa Biopharma – GBS as an emerging option Hansa has a more complex value profile where GBS is not yet fully priced as a core asset. Evidence base 1. Indirect Phase 2 data (imlifidase in GBS): * Clinical signal in Guillain-Barré syndrome * Validates mechanism in patient population 2. Phase 1 data (HNSA-5487, NICE-01): * Rapid and robust IgG reduction * Confirms biological activity in humans 3. Development strategy: * Planned interactions with FDA * Intention to move towards late clinical phase after 2026 👉 Hansa thus has: * mechanism validation * clinical signal (indirect Phase 2) * next-generation drug candidate But still lacks: * direct late-phase data for HNSA-5487 in GBS 👉 GBS is therefore still an early but growing value driver, rather than a centrally priced asset. ⸻ 📈 Catalysts (Hansa) * FDA interactions (1H 2026) * start of late clinical phase for HNSA-5487 * first patient data in GBS 👉 These constitute the three most important trigger points for potential re-rating: * FDA meetings reduce regulatory uncertainty * Phase 3 initiation moves the program towards value realization * clinical data will be the first real test of the next-generation molecule ⸻ 3. Valuation Implication Annexon * GBS: ~50–80% of EV * The market prices a high probability of commercialization Hansa * GBS: ~10–25% of EV (risk-adjusted theoretical) * The market discounts a significantly lower probability for HNSA-5487 in GBS ⸻ 4. Relative Market Position See image ⸻ 5. Investment Logic Annexon * Priced for GBS to likely be realized * Limited further upside without strong outperformance in data * High binary risk in case of negative outcome Hansa * Priced with low implicit probability for GBS success * Already has a commercial base (imlifidase) * Pipeline provides additional optionality ⸻ 6. Conclusion The market treats: * Annexon as a near-monetizable GBS case * Hansa Biopharma as an early platform case where GBS is not yet priced in 👉 The upside in Hansa is structurally larger because re-rating can occur from a very low base, while Annexon is already trading near a scenario where GBS success is largely discounted.
- ·1 päivä sittenWhat are people's expectations for Q1?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | - | - | ||
| 100 | - | - | ||
| 15 | - | - | ||
| 148 | - | - | ||
| 332 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 377 422 | 377 422 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 377 422 | 377 422 | 0 | 0 |